ZTS — Zoetis Inc. stock price, charts and financials

QT35Zoetis Inc.

Zoetis Inc. (NYSE: ZTS) is a Healthcare company in the Drug Manufacturers - General industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
76.04
-1.06-1.37%
ZTSQT35Zoetis Inc.·NYSE
76.04-1.37%
Earnings
Down 1.4% — Earnings due 2026-08-06 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E12.61EPS (ttm)6.03Insider Own0.13%Shs Outstand419.23MPerf Week-1.90%
Market Cap31.88BForward P/E10.34EPS next Y7.35Insider Trans-1.59%Shs Float418.38MPerf Month0.82%
Enterprise Value39.18BPEG1.36EPS next Q-Inst Own92.06%Short Float4.49%Perf Quarter-32.52%
Income2.64BP/S3.35EPS this Y8.71%Inst Trans-Short Ratio2.62Perf Half Y-39.14%
Sales9.51BP/B9.86EPS next Y12.18%ROA17.44%Short Interest18.79MPerf YTD-39.56%
Book/sh7.71P/C16.43EPS next 5Y9.24%ROE62.41%52W High160.49 -52.62%Perf Year-48.41%
Cash/sh4.63P/FCF15.17EPS past 3/5Y10.27% 11.97%ROIC21.79%52W Low71.47 6.39%Perf 3Y-59.96%
Dividend Est.2.12 (2.79%)EV/EBITDA9.72Sales past 3/5Y5.42% 7.24%Gross Margin70.75%Volatility2.93% 2.70%Perf 5Y-62.33%
Dividend TTM2.09 (2.75%)EV/Sales4.12EPS Y/Y TTM10.24%Oper. Margin37.57%ATR (14)2.40Perf 10Y52.11%
Dividend Ex-DateJul 20, 2026Quick Ratio1.91Sales Y/Y TTM2.73%Profit Margin27.79%RSI (14)47.33Recom2.48
Dividend Gr. 3/5Y15.44% 20.11%Current Ratio3.15EPS Q/Q3.38%SMA200.21%Beta0.72Target Price101.50
Payout33.64%Debt/Eq2.85Sales Q/Q1.89%SMA50-1.31%Rel Volume1.00Prev Close77.10
Employees14,500LT Debt/Eq2.83EarningsAug 06SMA200-30.75%Avg Volume7.60MPrice76.04
IPO DateFeb 01, 2013Option/ShortYes / YesEPS/Sales Surpr.-4.60% -1.71%Net Debt/EBITDA1.81Volume7,600,945Change-1.37%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-27-26ReiteratedUBSNeutral$99$85
Jul-22-26ReiteratedMorgan StanleyOverweight$115$99
Jul-06-26ReiteratedHSBCBuy$140$95
Jul-01-26ReiteratedBarclaysEqual Weight$136$85
Jun-26-26ReiteratedStifel NicolausBuy$95$85
May-27-26DowngradeArgus ResearchBuyHold
May-22-26ReiteratedStifel NicolausBuy$105$95
May-15-26ReiteratedMorgan StanleyOverweight$160$115
May-08-26ReiteratedStifel NicolausBuy$130$105
May-08-26ReiteratedUBSNeutral$130$99
Latest News
Aug-04-26
Aug-03-26
Jul-29-26
Jul-27-26
Jul-24-26
Jul-23-26
Jul-22-26
Company

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Ownership
Total institutional ownership92.06%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue9,5099,4679,2568,5448,0807,7766,6756,2605,825
Cost of Goods Sold Incl. D&A2,7812,7942,8602,7102,6042,4642,2172,1472,028
Gross Profit6,7286,6736,3965,8345,4765,3124,4584,1133,797
Selling, General and Administrative Excl. Other2,4032,3782,3182,1512,0092,0011,7261,6381,482
Research and Development721698686614539508463457432
Other Operating Expense3100000002
Operating Income3,5733,5973,3923,0692,9282,8032,2692,0181,881
Interest Expense241243242258237236249242212
Unusual Expense
Non-Operating Income (Expense)-246-17125-35-79-242521
Net Income Before Taxes3,3083,3603,1332,9362,6562,4881,9961,8011,690
Income Taxes665687637596545454360301266
Consolidated Net Income2,6432,6732,4862,3442,1142,0371,6381,5001,428
Net Income From Continuing Operations2,6432,6732,4962,3402,1112,0341,6361,5001,424
Net Income2,6432,6732,4862,3442,1142,0371,6381,5001,428
EPS (Recurring)6.046.035.475.084.514.293.443.142.96
EPS (Basic, Before Extraordinaries)6.046.035.475.084.514.293.443.142.96
EPS (Diluted)6.036.025.475.074.494.273.423.112.93
EBITDA4,0304,0693,8723,6853,3583,1722,6862,4552,210
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio12.6120.9029.7938.9332.6457.1548.3942.5629.19
Price To Sales Ratio3.375.897.9910.658.5114.8811.8010.117.09
Gross Margin70.7570.4969.1068.2867.7768.3166.7965.7065.18
Operating Margin37.5738.0036.6535.9236.2436.0533.9932.2432.29
Net Margin27.7928.2326.8627.4326.1626.2024.5423.9624.52
Shares Outstanding422443454461469474476478483
Market Capitalization32,08955,73873,97090,98868,732115,67078,77863,26341,316
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$185.07$153.07$121.08$89.09$57.09 Close Price0.00M0.64M1.27M1.91M2.54MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Stetter MarkDirectorMay 21 '26Option Exercise0.001,57201,572May 26
PARENT LOUISE MDirectorMay 20 '26Option Exercise0.0022,317028,394May 21
DAMELIO FRANK ADirectorMay 13 '26Buy75.396,650501,34421,458May 13
Bisaro PaulDirectorMay 13 '26Buy75.882,000151,75027,862May 13
MCCALLISTER MICHAEL BDirectorMay 11 '26Buy77.763,000233,27324,524May 12
Esch KevinExecutive Vice PresidentApr 30 '26Option Exercise0.005190653May 01
Sarbaugh KeithExecutive Vice PresidentMar 31 '26Option Exercise0.001,52803,870Apr 01
PARENT LOUISE MDirectorFeb 19 '26Option Exercise0.001,619016,879Feb 23
Reed Willie MDirectorFeb 19 '26Option Exercise0.001,619012,864Feb 23
MCCALLISTER MICHAEL BDirectorFeb 19 '26Option Exercise0.001,61901,622Feb 23
Norden GregoryDirectorFeb 19 '26Option Exercise0.001,61901,619Feb 23
Broadhurst VanessaDirectorFeb 19 '26Option Exercise0.001,61904,437Feb 23
FULLER JULIEExecutive Vice PresidentFeb 19 '26Option Exercise0.0075001,353Feb 23
Joseph WettenyChief Financial OfficerFeb 19 '26Option Exercise0.004,101022,816Feb 23
PECK KRISTIN CChief Executive OfficerFeb 19 '26Option Exercise0.0014,7090108,691Feb 23
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.